Importantly, the people who see the upside are the Board of...

Importantly, the people who see the upside are the Board of Directors;

"The listing of Phylogicas shares on the Frankfurt Stock Exchange is a key element of our strategy to raise the companys profile with the international financial community.....This is an exciting and potentially transformational period for Phylogica as we scale up the commercialization of our unique drug discovery platform", said Chairman Dr Doug Wilson.

Phylogica is rapidly building a reputation in Big Pharma circles in Europe. How do we know? Well, for one thing the German investment and reseach group Close Brothers make the observation that "the partnership with Roche...has a particular importance for the company....given that Roche are very selective in choosing its development partners."

Secondly, Phylogica is presently involved in discussions with more than 12 companies including late term negotiations with both a top 5 and top 10 pharma company.

Frankfurt offers two key advantages;
1. The listing locates Phylogica in the European dealmaking centre of Big Pharma.
2. European institutional shareholders could have a powerful impact upon price discovery for Phylogica. The listing will help provide the liquidity which will drive the share price as deals are done and as the potential for Phylogica's drug discovery engine and business model are more fully appreciated by sophisticated investors.

The research paper by Close Brothers Seydler is available on the PYC website. Note, Wilson also discusses the "succesful and timely delivery of new partnerships" in the Frankfurt announcement. The Chairman is not setting Phylogica up for a humiliating failure to deliver but advising shareholders to expect a strong flow of good news in the next 6 to 12 months.